Valiant Laboratories (NSE:VALIANTLAB) Debt-to-Equity: N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VALIANTLAB Valiant Laboratories Ltd NSE:VALIANTLAB
53 GF Score
Price ₹100.52
GF Value ₹149.22
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Valiant Laboratories Debt-to-Equity?

Valiant Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Valiant Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Valiant Laboratories's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Valiant Laboratories's Debt-to-Equity or its related term are showing as below:

NSE:VALIANTLAB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.5   Max: 0.86
Current: 0.15

During the past 6 years, the highest Debt-to-Equity Ratio of Valiant Laboratories was 0.86. The lowest was 0.01. And the median was 0.50.

NSE:VALIANTLAB's Debt-to-Equity is ranked better than
65.35% of 811 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs NSE:VALIANTLAB: 0.15

Valiant Laboratories  (NSE:VALIANTLAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Valiant Laboratories Debt-to-Equity Related Terms

Valiant Laboratories Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Valiant Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valiant Laboratories Debt-to-Equity Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Equity
Get a 7-Day Free Trial 0.86 0.60 0.32 0.52 0.15

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.17 N/A 0.15 N/A

NSE:VALIANTLAB vs ZTS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valiant Laboratories Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's Debt-to-Equity falls into.


NSE:VALIANTLAB
53GF Score
Valiant Laboratories Ltd NSE:VALIANTLAB
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valiant Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Valiant Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(173.212 + 288.907) / 3108.851
=0.15

Valiant Laboratories's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued. The current stock price of ₹100.52 is trading 32.6% below its estimated GF Value™ of ₹149.22. GuruFocus considers Valiant Laboratories to be Possible Value Trap.

Key valuation signals for NSE:VALIANTLAB:

  • Debt-to-Equity: N/A
  • GF Value™: ₹149.22 vs. price of ₹100.52 (32.6% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valiant Laboratories Business Description

Other Exchanges 543998:India
Address Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
53GF Score

Get the complete analysis for NSE:VALIANTLAB

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹100.52
Price
₹149.22
GF Value